Characterization of a Single-Chain Variable Fragment Recognizing a Linear Epitope of Aβ: A Biotechnical Tool for Studies on Alzheimer's Disease?

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Dornieden, Silke ^a   Müller Schiffmann, Andreas ^b   Sticht, Heinrich ^c   Jiang, Nan ^a   Cinar, Yeliz ^a   Wördehoff, Michael ^b   Korth, Carsten ^b   Funke, Susanne Aileen ^a,d   Willbold, Dieter ^a,b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Bioanalytik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-8]; AMYLOID BETA PROTEIN[2-8]; AMYLOID BETA PROTEIN[3-8]; EPITOPE; IC16 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PFA1; MONOCLONAL ANTIBODY PFA2; MONOMER; OLIGOMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THIOFLAVINE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMYLOID PLAQUE; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG PROTEIN BINDING; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EX VIVO STUDY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIGAND BINDING; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN AGGREGATION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SURFACE PLASMON RESONANCE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; LIGANDS; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEURODEGENERATIVE DISEASES; PERMEABILITY; PLASMIDS; PROTEIN BINDING; SEQUENCE ALIGNMENT; SINGLE-CHAIN ANTIBODIES; THIAZOLES;

MUS;

EID: 84875455396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059820     Document Type: Article

References (56)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM, (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers & Dementia 3: 186-191.
2. Citron M, (2010) Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9: 387-398.
3. Haass C, Selkoe DJ, (1993) Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 75: 1039-1042.
4. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, et al. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736.
5. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, et al. (1989) Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 57: 115-126.
6. Puzzo D, Arancio O (2012) Amyloid-beta Peptide: Dr. Jekyll or Mr. Hyde? J Alzheimers Dis.
7. Hardy JA, Higgins GA, (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
8. Selkoe DJ, (1991) The molecular pathology of Alzheimer's disease. Neuron 6: 487-498.
9. Finder VH, Glockshuber R, (2007) Amyloid-beta aggregation. Neurodegener Dis 4: 13-27.
10. Haass C, Selkoe DJ, (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
11. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95: 6448-6453.
12. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, et al. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866-2875.
13. Walsh DM, Selkoe DJ, (2007) A beta oligomers- a decade of discovery. J Neurochem 101: 1172-1184.
14. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919.
15. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98: 8850-8855.
16. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, et al. (2006) Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281: 4292-4299.
17. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, et al. (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24: 6144-6151.
18. Haas C, (2012) Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease. J Alzheimers Dis 28: 241-281.
19. Callaway E, (2012) Alzheimer's drugs take a new tack. Nature 489: 13-14.
20. Nordberg A, (2007) Amyloid imaging in Alzheimer's disease. Curr Opin Neurol 20: 398-402.
21. Nordberg A, (2008) Amyloid imaging in Alzheimer's disease. Neuropsychologia 46: 1636-1641.
22. Valadon P, Garnett JD, Testa JE, Bauerle M, Oh P, et al. (2006) Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci U S A 103: 407-412.
23. Lichtlen P, Mohajeri MH, (2008) Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 104: 859-874.
24. Holliger P, Hudson PJ, (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
25. Wang YJ, Zhou HD, Zhou XF, (2010) Modified immunotherapies against Alzheimer's disease: toward safer and effective amyloid clearance. J Alzheimers Dis 21: 1065-1075.
26. Liu R, Yuan B, Emadi S, Zameer A, Schulz P, et al. (2004) Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43: 6959-6967.
27. Robert R, Dolezal O, Waddington L, Hattarki MK, Cappai R, et al. (2009) Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng Des Sel 22: 199-208.
28. Solorzano-Vargas RS, Vasilevko V, Acero G, Ugen KE, Martinez R, et al. (2008) Epitope mapping and neuroprotective properties of a human single chain FV antibody that binds an internal epitope of amyloid-beta 1-42. Mol Immunol 45: 881-886.
29. Cai J, Wang S, Zhong Y, Cheng J, Ji Z, et al. (2003) Screening and characterization of human single-chain Fv antibody against beta-amyloid peptide 40. Neuroreport 14: 265-268.
30. Wang YJ, Gao CY, Yang M, Liu XH, Sun Y, et al. (2010) Intramuscular delivery of a single chain antibody gene prevents brain Abeta deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain, behavior, and immunity 24: 1281-1293.
31. Cattepoel S, Hanenberg M, Kulic L, Nitsch RM, (2011) Chronic intranasal treatment with an anti-Abeta(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 6: e18296.
32. Eswar N, Eramian D, Webb B, Shen MY, Sali A, (2008) Protein structure modeling with MODELLER. Methods Mol Biol 426: 145-159.
33. Gardberg AS, Dice LT, Ou S, Rich RL, Helmbrecht E, et al. (2007) Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci U S A 104: 15659-15664.
34. Hooft RW, Vriend G, Sander C, Abola EE, (1996) Errors in protein structures. Nature 381: 272.
35. Wallace AC, Laskowski RA, Thornton JM, (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8: 127-134.
36. Muller-Schiffmann A, Marz-Berberich J, Andreyeva A, Ronicke R, Bartnik D, et al. (2010) Combining Independent Drug Classes into Superior, Synergistically Acting Hybrid Molecules. Angew Chem Int Ed Engl 49: 8743-8746.
37. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, et al. (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356: 577-582.
38. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, et al. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A85: 5879-5883.
39. Leliveld SR, Stitz L, Korth C, (2008) Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein. Biochemistry 47: 6267-6278.
40. Schonfeld D, Matschiner G, Chatwell L, Trentmann S, Gille H, et al. (2009) An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci U S A 106: 8198-8203.
41. Johansson AS, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, et al. (2006) Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J 273: 2618-2630.
42. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, et al. (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271: 22908-22914.
43. Kim S, Cheung LH, Zhang W, Rosenblum MG, (2007) Improved expression of a soluble single chain antibody fusion protein containing tumor necrosis factor in Escherichia coli. Appl Microbiol Biotechnol 77: 99-106.
44. Muller-Schiffmann A, Petsch B, Leliveld SR, Muyrers J, Salwierz A, et al. (2009) Complementarity determining regions of an anti-prion protein scFv fragment orchestrate conformation specificity and antiprion activity. Mol Immunol 46: 532-540.
45. Hsu E SL, (1992) Primary structure of immunoglobulins through evolution. Curr Opin Struct Biol 2: 422-431.
46. LeVine H 3rd (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Scity 2: 404-410.
47. Tycko R, (2006) Molecular structure of amyloid fibrils: insights from solid-state NMR. Q Rev Biophys 39: 1-55.
48. Klaver AC, Finke JM, Digambaranath J, Balasubramaniam M, Loeffler DA, (2010) Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol 10: 115-119.
49. Klaver AC, Patrias LM, Coffey MP, Finke JM, Loeffler DA, (2010) Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J Neurosci Methods 187: 263-269.
50. Sohn JH, So JO, Kim H, Nam EJ, Ha HJ, et al. (2007) Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice. Biochem Biophys Res Commun 361: 800-804.
51. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, et al. (1995) Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270: 9564-9570.
52. Gardberg A, Dice L, Pridgen K, Ko J, Patterson P, et al. (2009) Structures of Abeta-related peptide-monoclonal antibody complexes. Biochemistry 48: 5210-5217.
53. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S, (1996) Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 215: 173-176.
54. Schlenzig D, Manhart S, Cinar Y, Kleinschmidt M, Hause G, et al. (2009) Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry 48: 7072-7078.
55. Tycko R, (2006) Molecular structure of amyloid fibrils: insights from solid-state NMR. Quarterly reviews of biophysics 39: 1-55.
56. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.